Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

more >

Recent News

04/08/20

Summary Toggle Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program WARREN, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on
04/06/20

Summary Toggle Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

WARREN, N.J. , April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter and
04/01/20

Summary Toggle Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

WARREN, N.J. , April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, closed its previously announced registered direct offering of 1,275,000 shares of its common stock at a purchase price of

more >

Stock Quote

more >

Bellerophon (: )

Data as of 04/09/20 3:21 PM EDT

more >

Presentations

COVID 19 Overview

03/31/20

COVID 19 Overview 1.2 MB
Corporate Presentation

02/18/20

Corporate Presentation 1.3 MB
PFF 2019 Poster - Sub-Group Analysis

11/08/19

PFF 2019 Poster - Sub-Group Analysis 217.3 KB
PFF 2019 Poster - Actigrpahy Endpoint

11/08/19

PFF 2019 Poster - Actigrpahy Endpoint 252.4 KB
American College of Chest Physicians Conference Presentation

10/23/19

American College of Chest Physicians Conference Presentation 537.5 KB
KOL Day Presentation

05/30/19

KOL Day Presentation 4 MB
2019 ATS PH-ILD Presentation

05/21/19

2019 ATS PH-ILD Presentation 452.8 KB
ATS 2019 PH-ILD Poster

05/21/19

ATS 2019 PH-ILD Poster 310.5 KB
2019 PVRI Poster – iNO DDI Study

02/02/19

2019 PVRI Poster – iNO DDI Study 339.9 KB
2019 PVRI Poster – Actigraphy in PH-PF

02/02/19

2019 PVRI Poster – Actigraphy in PH-PF 562 KB
Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

08/09/17

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan 4.5 MB
2017 ATS Poster - PH-IPF

05/23/17

2017 ATS Poster - PH-IPF 2.2 MB
2017 ATS Poster - PH-COPD

05/23/17

2017 ATS Poster - PH-COPD 3 MB
2017 ISHLT Poster

04/06/17

2017 ISHLT Poster 417.9 KB
2016 ATS Poster

05/19/16

2016 ATS Poster 971 KB
2015 PHPN Poster

09/19/15

2015 PHPN Poster 684.5 KB

Investors

Corporate Profile

Recent News

Stock Quote

Upcoming Events

Presentations

COVID 19 Overview

Corporate Presentation

PFF 2019 Poster - Sub-Group Analysis

PFF 2019 Poster - Actigrpahy Endpoint

American College of Chest Physicians Conference Presentation

KOL Day Presentation

2019 ATS PH-ILD Presentation

ATS 2019 PH-ILD Poster

2019 PVRI Poster – iNO DDI Study

2019 PVRI Poster – Actigraphy in PH-PF

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

2017 ATS Poster - PH-IPF

2017 ATS Poster - PH-COPD

2017 ISHLT Poster

2016 ATS Poster

2015 PHPN Poster